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The potential of the metal-binding protein, metallothionein, in assessing the progression of normal oesophagus through
Barrett’s to adenocarcinoma was investigated. Metallothionein was quantitatively determined in resected tissues from patients
undergoing oesophagectomy for high grade dysplasia/adenocarcinoma and in biopsies from patients with Barrett’s syndrome.
In 10 cancer patients, metallothionein concentrations in adenocarcinoma were not signiﬁcantly different from normal
oesophagus, although six had elevated metallothionein concentrations in the metaplastic tissue bordering the adenocarcinoma.
In 17 out of 20 non-cancer patients with Barrett’s epithelium, metallothionein was signiﬁcantly increased by 108% (P50.004).
There was no association between the metallothionein levels in Barrett’s epithelium and the presence of inﬂammatory cells,
metaplasia or dysplasia. Metallothionein is a marker of progression from normal to Barrett’s epithelium but is not increased in
oesophageal adenocarcinoma.
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Chronic irritation of the oesophagus by reﬂux of acidic gastric
juices can lead to Barrett’s oesophagus which is characterised by
columnar metaplasia which replaces the normal stratiﬁed squa-
mous epithelium in the lower third of the oesophagus. Barrett’s
oesophagus is considered to be a premalignant lesion and in some
patients leads to adenocarcinoma of the oesophagus, a cancer with
poor prognosis and of increasing prevalence in the Western World
(Jankowski et al, 1999; Krishnadath et al, 2001). It is generally
accepted that cancer evolves from Barrett’s oesophagus by progres-
sion from metaplasia, to low-grade dysplasia, high-grade dysplasia
and then to adenocarcinoma. Thus, biopsy with histological
demonstration of high grade dysplasia provides the main evidence
for a transition from Barrett’s to adenocarcinoma (Ortiz-Hidalgo et
al, 1998; Krishnadath et al, 2001). However the staging of Barrett’s
oesophagus is subject to considerable inter- and intraobserver
variation. Consequently interest is mounting in a range of biologi-
cal markers that may help to support histological diagnosis and
improve the efﬁcacy of surveillance programs (Krishnadath et al,
2001).
Metallothionein (MT) is a low molecular weight, cysteine-rich
protein, with metal-binding and antioxidant properties. It is
rapidly induced by a variety of agents including inﬂammatory cyto-
kines, hormones and cytotoxic agents. Although the primary role
of MT is controversial, it is known to regulate Zn homeostasis
and be involved in cellular defence mechanisms. Its ability to
donate Zn to many Zn-requiring enzymes and transcription factors
suggest a role for MT in the processes of cell proliferation and
differentiation (reviewed by Cherian et al, 1994; Coyle et al,
2002). MT is expressed in a variety of human cancers where it
has been found to correlate with proliferative activity, tumour cell
progression and resistance to anti-cancer drugs (Cherian et al,
1994). Increased MT expression has been found in squamous cell
carcinomas of the oesophagus (Hishikawa et al, 1999), serous ovar-
ian tumours (Tan et al, 1999), breast carcinomas (Fresno et al,
1993), astrocytomas (Hiura et al, 1998) and bladder cancers (Sens
et al, 2000). High MT expression has been found in metaplastic,
dysplastic and cancerous gastric tissues but levels were independent
of tumour stage, degree of differentiation and tumour type (Ebert
et al, 2000). In one study, the 5 year survival rate of patients with
gastric adenocarcinoma was much poorer in those patients expres-
sing two or more markers of proliferative activity that included
MT, glutathione-S-transferase-p or P-glycoprotein (Monden et al,
1997). On the other hand, reduced MT expression was found in
human colorectal tumours (Duncan and Reddel, 1999), seminomas
(Chin et al, 1993), hepatocellular tumours (Waalkes et al, 1996)
and gastrointestinal neoplasms (Janssen et al, 2000) and was mainly
associated with poor prognosis.
The diagnostic potential of MT in the progression of normal
oesophagus through Barrett’s to adenocarcinoma has not been
elucidated and is the subject of this study.
METHODS
Samples of approximately 200 mg of normal oesophagus, premalig-
nant tissue (clinically Barrett’s oesophagus), carcinoma and normal
gastric tissue were taken from 12 patients who underwent oesopha-
gectomy or oesophago-gastrectomy. The distance of the resected
tissue from the anatomical gastro-oesophageal junction was deter-
mined and the sample was immediately frozen and stored at
7708C until analysed. In a second study, biopsies were taken from
20 patients with a histological record of Barrett’s epithelium, and
who were undergoing a yearly follow-up to determine the progres-
sion of the disease. Nine of these patients were being followed after
fundoplication surgery for severe oesophageal reﬂux. Multiple
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columnar epithelium and from macroscopically normal stratiﬁed
squamous epithelium at least 1–2 cm above the Barrett’s epithe-
lium. Biopsy specimens were ﬁxed with 10% neutral buffered
formalin and sent for routine histology. A series of fresh biopsy
samples was immediately frozen in liquid nitrogen and then stored
at 7708C. Tissue and biopsy samples were diluted 1:5 with cold
homogenate buffer (10 mM Tris-HCl, pH 8.2) and homogenised
using a Potter-Elvehjem homogeniser (Wheaton, NJ, USA). The
homogenates were then boiled in a water bath for 2 min and then
centrifuged for 4 min at 14000 g. Metallothionein was determined
by the cadmium-haemoglobin binding assay (Eaton and Toal,
1982). Protein was determined with SERVA-G Coomasie blue
dye reagent (Lott et al, 1983) using a Cobas Bio Centrifugal Analy-
ser (Hoffman La Roche, Basel, Switzerland) and human serum
albumin as standard. Results are reported as the mean+s.e.m.
Where appropriate, signiﬁcance was determined by the Wilcoxon
signed-rank test for paired differences, paired t-test for two sample
means and Student’s t-test for independent samples. This study was
approved by the Research Ethics Committee of the Royal Adelaide
Hospital.
RESULTS
Metallothionein concentrations in the macroscopically normal
squamous epithelium were 193+12 pmol Cd bound mg
71 protein
(n=31), 195+28 (n=13) and 194+19 (n=25) in the upper, middle
and lower oesophagus. MT concentration in clinically normal
gastric tissue was 446+186 pmol Cd bound mg
71 protein
(n=59). Higher MT levels (P50.001) were found in the upper half
of the stomach (489+54, n=20) than lower half (148+14, n=20)
but there was no signiﬁcant difference between equivalent positions
along the greater and lesser curves of the stomach.
In 10 patients with adenocarcinoma (Table 1), MT concentra-
tions in metaplastic tissue immediately bordering the
adenocarcinoma (354+93 pmol Cd bound mg
71 protein) and in
adenocarcinoma (214+28) were not signiﬁcantly different from
macroscopically normal oesophagus (226+28). However in the
bordering metaplastic tissues of six out of 10 patients with adeno-
carcinoma and in dysplastic tissue from two other patients, MT
concentrations were on average two-fold higher than those in
normal oesophagus. The levels of MT in adenocarcinoma were
unremarkable and there was no obvious association between the
MT content and the histological grading.
Metallothionein concentrations were increased in Barrett’s
epithelium in 17 out of 20 patients by an average of 108% (Table
2). The mean MT concentration in normal and Barrett’s epithe-
lium was 204+22 (pmol Cd bound mg
71 protein; mean+s.d.)
and 411+68, respectively. The difference between MT concentra-
tions in normal and Barrett’s epithelium was highly signiﬁcant
(P50.004). There was no association between the MT levels in
Barrett’s epithelium and the histological diagnosis of inﬂammation,
metaplasia or dysplasia.
DISCUSSION
It has been argued that in Barrett’s oesophagus there is a large intra-
and interobserver variation in the reporting of various grade dyspla-
sia with inﬂammatory atypia making the diagnosis problematic.
Thus it can be difﬁcult to monitor the progression of oesophagitis
to dysplasia in order to detect cancer at a curable stage (Ortiz-
Hidalgo et al, 1998). This has led to the search for new objective
indicators which may complement and help reduce the observer
variability with histological diagnosis. MT is a potential marker of
carcinogenesis and its expression in human cancers can be up- or
down-regulated (Cherian et al, 1994). Few studies have focused
on the expression of MT in human oesophageal tumours and this
is the ﬁrst to quantitatively measure the concentration of MT in
human adenocarcinoma of the oesophagus and in Barrett’s epithe-
lium, which is generally considered to be the premalignant lesion,
although the primary cells leading to adenocarcinoma have not
been identiﬁed. In one study, in situ hybridisation with MT DNA
probes and immunochemistry was used to determine MT mRNA
and MT protein expression in resected oesophageal tissue from
patients with squamous cell carcinoma. It was concluded that MT
expression was a potential marker of the proliferative and metastatic
behaviour of this cancer (Hishikawa et al, 1997, 1999). Here we
demonstrate that MT expression was not increased above matched
normal-appearing oesophagus in 10 patients we investigated with
adenocarcinoma. In each case, there was histological conﬁrmation
that the adenocarcinoma arose from columnar lined Barrett’s
mucosa. Thus comparison of the MT levels in the adenocarcinoma
with those in Barrett’s epithelium indicates that MT expression is
down regulated in neoplastic progression. Similar changes in MT
concentration have been demonstrated in stomach adenocarcinoma.
In a study of 35 patients with gastric adenocarcinoma where MT
was quantitatively measured on resected tissues, it was found that
MT was signiﬁcantly lower in adenocarcinoma compared to that
in normal-appearing gastric mucosa (Janssen et al, 2000). In
another study on 34 patients with gastric cancer, MT immunoreac-
tivity in the cytoplasm and surface of the tumours was absent or
low in 19 cases, moderately increased in 12 patients, and greatly
increased in three cases (Ebert et al, 2000). There was no association
between immunoreactivity tumour stage, grade of differentiation or
tumour type. This is not unexpected however, as MT is induced by
a variety of inﬂammatory mediators as well as cytotoxic agents and
irradiation. Thus any pre-surgical radiotherapy and/or chemother-
apy might affect the level of expression and localisation of MT in
these studies. Our ﬁnding that MT appears quantitatively higher
in the cardia and fundus than in lower regions of the stomach
may reﬂect the glandular composition of these areas. Intense immu-
noreactivity has been reported in goblet cells and at the foveolar
neck of gastric glands (Ebert et al, 2000).
Others have demonstrated that MT is responsive to inﬂamma-
tory and pre-neoplastic changes in normal tissues. In gastric
cancer patients, intense immunostaining for MT was found in
adjacent metaplastic and dysplastic tissues in 17 out of 34 patients
(Ebert et al, 2000). Our study of 20 patients with Barrett’s epithe-
lium clearly demonstrates that MT is increased in Barrett’s tissue
above that in normal oesophagus. The underlying reason for this
increase remains unknown. There is evidence in mice that overex-
pression of MT in mutagen-subjected colorectal crypts arises from
random stem cell somatic mutation (Jasani et al, 1998; Cook et al,
2000). Such a mechanism could account for overexpression of MT
in Barrett’s oesophagus while loss of this gain mutation might
occur in those lines of cells that become cancer.
In the present study, there was no obvious association in MT
expression between the histological markers of the presence of
inﬂammatory cells, metaplasia or dysplasia. Indeed, two of four
patients with histologically stable Barrett’s epithelium had the high-
est levels of MT. This may indicate that MT expression in Barrett’s
mucosa is more closely related to the higher MT levels found in the
specialised mucosa than the pathobiology associated with cancer.
Barrett’s mucosa is composed of heterogenous cell types. Three
histological patterns have been identiﬁed including (a) small colum-
nar intestinal-like cells with mucin containing goblet cells and crypt
like glands containing Paneth and endocrine cells, (b) fundic muco-
sa indistinguishable from that in the stomach showing pits with
mucous-secreting cells and a few parietal and chief cells and (c)
normal gastric cardiac mucosa (Ortiz-Hidalgo et al, 1998). Several
studies have indicated that the intestinal type with metaplasia is
more likely to undergo neoplastic progression than the fundic and
cardiac form (Hamilton and Smith, 1987; Filipe and Jankowski,
1993). Interestingly, goblet cells show intense immunostaining for
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of the specialised mucosa. In addition, in rats we have shown that
MT immunostaining of small intestinal segments is localised to
crypt cells and in particular, Paneth cells (Tran et al, 1999). Barrett’s
epithelium is often complex and may contain multiple histological
patterns. The ﬁnding of high-grade dysplasia in metaplastic epithe-
lium remains the best predictor of increased risk of cancer. Whether
MT might prove useful in predicting histological types of columnar
change warrants investigation. Immunohistochemical studies will be
required to fully identify the specialised cells involved in the
increased MT expression. In addition, longitudinal studies on
patients with oesophageal reﬂux without Barrett’s epithelium, is
required to determine whether MT is a predictor of progression
from normal stratiﬁed squamous epithelium into Barrett’s oesopha-
gus. The level of MT in Barrett’s epithelium also might prove
relevant to the responsiveness of the oesophagus to pre-surgical
radiotherapy and chemotherapy but again this remains to be inves-
tigated. For the present we believe the high levels of MT found in
columnar metaplastic tissues is an interesting ﬁnding which
warrants further investigation.
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Table 1 Characteristics of patients, histological diagnosis and metallothionein levels in normal, transitional and cancerous oesophageal tissue
MT (pmol mg
71 protein)
Patient Age Sex Normal Transitional Cancer Treatment
b Histology
1 44 M 86 108 85 no Metastatic moderately differentiated adenocarcinoma
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Table 2 Characteristics of patients, histological diagnosis and metallothionein levels in normal and Barett’s epithelium
MT (pmol mg
71 protein)
Patient Age Sex
Barrett’s
(cm) Surgery Normal Barrett’s % increase Histology
1 73 F 5 f 185 1075 482 Stable
a
2 73 M 2 f 172 669 290 Stable
3 57 M 3 f 108 71 734 Stable
4 41 F 10 f 193 420 117 Stable
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7 54 M 3 – 161 268 66 Inﬂammatory cells
8 70 M 2 – 138 320 133 Inﬂammatory cells
9 40 F 7 – 249 361 45 Metaplasia
10 38 M 8 f 210 223 6 Metaplasia
11 52 M 8 f 253 357 41 Metaplasia
12 47 M 4 f 144 283 97 Metaplasia/inﬂammatory cells
13 71 M 12 f 181 359 99 Metaplasia/inﬂammatory cells
14 67 F 7 – 370 1349 265 Metaplasia/inﬂammatory cells
15 66 M 4 – 197 171 713 Metaplasia/inﬂammatory cells
16 81 F 9 – 133 240 81 Metaplasia/inﬂammatory cells
17 80 M 5 – 118 171 44 Metaplasia/inﬂammatory cells
18 74 M 16 – 201 289 43 Metaplasia/inﬂammatory cells
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aBarrett’s epithelium with no other histology. Abbreviation: f, fundoplication.
Metallothionein in Barrett’s oesophagus
P Coyle et al
535
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(5), 533–536Coyle P, Philcox JC, Carey LC, Rofe AM (2002) Metallothionein: The multi-
purpose protein. Cell Mol Life Sci 59: 627–647
Duncan EL, Reddel RR (1999) Downregulation of metallothionein-IIA
expression occurs at immortalization. Oncogene 18: 897–903
Eaton DL, Toal BF (1982) Evaluation of the Cd/hemoglobin assay for the
rapid determination of metallothionein in biological tissues. Toxicol Appl
Pharmacol 66: 134–142
Ebert MPA, Gu ¨nther T, Hoffmann J, Yu J, Miehlke S, Schulz HU, Roessner A,
Korc M, Malfertheimer P (2000) Expression of metallothionein II in intest-
inal metaplasia, dysplasia, and gastric cancer. Cancer Res 60: 1995–2001
Filipe MI, Jankowski J (1993) Growth factors and oncogenes in Barrett’s
oesophagus and gastric metaplasia. Endoscopy 25: 637–641
Fresno M, Wu W, Rodriguez JM, Nadji M (1993) Localization of metal-
lothionein in breast carcinomas. An immunohistochemical study.
Virchows Arch A Pathol Anat Histopathol 423: 215–219
Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M,
Tachibana M, Nagasue N (1997) Overexpression of metallothionein corre-
lates with chemoresistance to cisplatin and prognosis in esophageal cancer.
Oncology 54: 342–347
Hamilton SR, Smith RR (1987) The relationship between columnar epithelial
dysplasia and invasive adenocarcinoma arising in Barrett’s esophagus. Am J
Clin Pathol 87: 210–312
Hishikawa Y, Koji T, Dhar DK, Kinugasa S, Yamaguchi M, Nagasue N (1999)
Metallothionein expression correlates with metastatic and proliferative
potential in squamous cell carcinoma of the oesophagus. Br J Cancer 81:
712–720
Hiura T, Khalid H, Yamashita H, Tokunaga Y, Yasunaga A, Shibata S (1998)
Immunohistochemical analysis of metallothionein in astrocytic tumors in
relation to tumor grade, proliferative potential, and survival. Cancer 83:
2361–2369
Jankowski JA, Wright NA, Meltzer SJ, Triadaﬁlopoulos G, Geboes K, Casson
AG, Kerr D, Young LS (1999) Molecular evolution of the metaplasia-
dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 154:
965–973
Janssen AM, van Duijn W, Oostendorp-Van De Ruit MM, Kruidenier L,
Bosman CB, Grifﬁoen G, Lamers CBHW, van Krieken JHJM, van de Velde
CJH, Verspaget HW (2000) Metallothionein in human gastrointestinal
cancer. J Pathol 192: 293–300
Jasani B, Campbell F, Navadi H, Schmid KW, Williams GT (1998) Clonal
overexpression of metallothionein is induced by somatic mutation in
morphologically normal colonic mucosa. J Pathol 182: 144–147
Krishnadath KK, Reid BJ, Wang KK (2001) Biomarkers in Barrett’s Esopha-
gus. Mayo Clin Proc 76: 438–446
Lott JA, Stephan VA, Pritchard Jr KA (1983) Evaluation of the Coomassie
brilliant blue G-250 method for urinary protein. Clin Chem 29: 1946–1950
Monden N, Abe S, Sutoh I, Hishikawa Y, Kinugasa S, Nagasue N (1997)
Prognostic signiﬁcance of the expressions of metallothionein,
glutathione-S-transferase-pi, and P-glycoprotein in curatively resected
gastric cancer. Oncology 54: 391–399
Ortiz-Hidalgo C, De La Vega G, Aguirre-Garcı ￿a J (1998) The histopathology
and biologic prognostic factors of Barrett’s esophagus. J Clin Gastroenterol
26: 324–333
Sens MA, Somji S, Lamm DL, Garrett SH, Slovinsky F, Todd JH, Sens DA.
(2000) Metallothionein isoform 3 as a potential biomarker for human
bladder cancer. Environ Health Perspect 108: 413–418
Tan Y, Sinniah R, Bay BH, Singh G (1999) Metallothionein expression and
nuclear size in benign, borderline, and malignant serous ovarian tumours.
J Pathol 189: 60–65
Tran CD, Butler RN, Howarth GS, Philcox JC, Rofe AM, Coyle P (1999)
Regional distribution and localization of zinc and metallothionein in the
intestine of rats fed diets differing in zinc content. Scand J Gastroenterol
34: 689–695
Waalkes MP, Diwan BA, Rehm S, Ward JM, Moussa M, Cherian MG, Goyer
RA (1996) Down-regulation of metallothionein expression in human and
murine hepatocellular tumors: association with the tumor-necrotizing and
antineoplastic effects of cadmium in mice. J Pharmacol Exp Ther 277:
1026–1033
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Metallothionein in Barrett’s oesophagus
P Coyle et al
536
British Journal of Cancer (2002) 87(5), 533–536 ã 2002 Cancer Research UK